Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

738
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
738
Drug Therapy01:28

Drug Therapy

96
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
96
Clinical Trials: Overview01:11

Clinical Trials: Overview

3.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.4K
Prescription, Nonprescription and Orphan Drugs01:02

Prescription, Nonprescription and Orphan Drugs

842
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
842
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

4.7K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
4.7K
Preclinical Development: Overview01:28

Preclinical Development: Overview

4.8K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.8K

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

European Society of Cardiology updated curriculum for heart failure nurses: developed by the Heart Failure Association, in collaboration with the Association of Cardiovascular Nurses and Allied Professions of the European Society of Cardiology.

European journal of heart failure·2026
Same author

Proteomic markers enhance mortality prediction in heart failure.

European heart journal·2026
Same author

Evidence and opportunities for preeclampsia and cardiovascular disease prevention in malaria endemic settings.

Communications medicine·2026
Same author

Maternal Readiness for Newborn Self-Care in the Early Postpartum Period: Associations with Maternal Psychophysical State and Declared Breastfeeding Readiness.

Journal of clinical medicine·2026
Same author

Balancing policy ambition and systems reality in expanding access to NCD medicines: lessons from Ghana and Georgia.

Health policy and planning·2026
Same author

Obesity Definitions and Hospital Stay in Older Adults with Heart Failure: A Post Hoc Analysis of a Prospective Cohort.

Cardiac failure review·2026

Video Experimental Relacionado

Updated: Sep 9, 2025

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations
11:15

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

Published on: July 24, 2021

4.8K

Mapa de ruta de WHF sobre las terapias combinadas con una sola píldora

Enrico G Ferro1,2, Gautam Satheesh3,4,5, José Castellano6

  • 1Richard A. and Susan F. Smith Center for Outcomes Research, Division of Cardiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States.

Global heart
|September 2, 2025
PubMed
Resumen
Este resumen es generado por máquina.

Las combinaciones de píldoras individuales (PCS) mejoran la adherencia al tratamiento de enfermedades cardiovasculares (ECV) y reducen el riesgo. Esta hoja de ruta aborda los obstáculos y ofrece soluciones para una aplicación más amplia del RCP, especialmente en entornos de escasos recursos.

Palabras clave:
Enfermedad cardiovascularLas polipíldorasPrevención de la enfermedadCombinaciones de píldoras individuales

Más Videos Relacionados

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.3K
High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
07:51

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

Published on: May 21, 2018

12.0K

Videos de Experimentos Relacionados

Last Updated: Sep 9, 2025

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations
11:15

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

Published on: July 24, 2021

4.8K
A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.3K
High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
07:51

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

Published on: May 21, 2018

12.0K

Área de la Ciencia:

  • Cardiología
  • Salud pública
  • Investigación de los sistemas sanitarios

Sus antecedentes:

  • Las enfermedades cardiovasculares (ECV) son la principal causa de muerte en el mundo.
  • La falta de adherencia al tratamiento es un obstáculo importante en la prevención y el tratamiento de las ECV.
  • Las combinaciones de píldoras individuales (SPC) ofrecen una estrategia para simplificar los regímenes de medicamentos y mejorar la adherencia del paciente.

Objetivo del estudio:

  • Sintetizar la evidencia clínica actual sobre las combinaciones de píldoras individuales (SPC) para el tratamiento de las enfermedades cardiovasculares (ECV).
  • Identificar las principales barreras que obstaculizan la aplicación generalizada y la accesibilidad de los RCP a nivel mundial.
  • Proponer soluciones concretas y específicas del contexto para mejorar la integración del RCP en las estrategias nacionales de salud.

Principales métodos:

  • Una revisión exhaustiva de las últimas pruebas clínicas relativas a los RCP.
  • Análisis de las aportaciones de los expertos mundiales y de los sistemas sanitarios para identificar los desafíos de la aplicación.
  • Desarrollo de una hoja de ruta con estrategias prácticas para la ampliación del RCP y la accesibilidad.

Principales resultados:

  • Los RCP mejoran efectivamente la adherencia al tratamiento y reducen el riesgo cardiovascular.
  • Las barreras clave incluyen limitaciones de fabricación, costos, obstáculos regulatorios y pautas clínicas inconsistentes.
  • La hoja de ruta ofrece soluciones a medida para diversos entornos de atención médica, dando prioridad a los países de ingresos bajos y medios.

Conclusiones:

  • Abordar las barreras identificadas es crucial para maximizar los beneficios de los RCP en la prevención de las ECV.
  • La aplicación de las soluciones propuestas puede mejorar el acceso y la utilización efectiva de los RCP.
  • Esta hoja de ruta sirve como un recurso vital para las partes interesadas que buscan mejorar la atención de las ECV a través de estrategias basadas en la evidencia y centradas en el paciente.